Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 0.47% and 1.77%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Johnson & Johnson (JNJ) Surpasses Q4 Earnings Estimates

Investors were initially unenthused with the report, sending shares of J&J down 1.7% in premarket trading.

J&J's Earnings Were Mixed. Why the Stock Is Falling.

J&J expects its Covid vaccine to generate $3 billion to $3.5 billion in sales this year.

J&J expects more than $3 billion in Covid vaccine sales this year in mixed quarterly report

Johnson & Johnson (NYSE: JNJ) has reported Q4 adjusted earnings of $2.13 per share, up 14.5% Y/Y over the $1.86 posted a year ago and marginally ahead of the consensus of $2.12. Net sales increased 10.4% Y/Y to $24.8 billion, missing the consensus of $25.29 billion.

Johnson & Johnson's FY21 COVID-19 Vaccine Sales Below Expectations

Johnson & Johnson shares slid 1.3% premarket Tuesday, after the consumer goods, pharmaceutical and medical device maker posted weaker-than-expected revenue for the fourth quarter. The company posted net income of $4.736 billion, or $1.77 a share, for the quarter, up from $1.738 billion, or 65 cents a share, in the year-earlier period.

J&J shares down 1.3% premarket after Q4 revenue lags consensus

Johnson & Johnson on Tuesday forecast $3 billion-$3.5 billion in revenue for its COVID-19 vaccine this year, more than the $2.39 billion it generated in 2021 even as the drugmaker faces manufacturing issues and uneven demand.

J&J expects up to $3.5 billion in COVID vaccine sales this year

NEW BRUNSWICK, N.J., Jan. 25, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2021.

Johnson & Johnson Reports Q4 and Full-Year 2021 Results

JNJ has prospered during the pandemic even though the stock price has lagged the S&P 500 Index over the past year. As a Dividend King, JNJ has been rewarding shareholders since before many of us were born and there is no reason to think that will not continue.

Johnson & Johnson: The Right Prescription For A Turbulent Market

AstraZeneca

Pfizer

A third booster dose of a COVID-19 vaccine from either AstraZeneca Plc (NASDAQ: AZN), Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX), or Johnson & Johnson (NYSE: JNJ) increases antibody levels significantly in those who have previously received two doses of Sinovac Biotech Ltd (NASDAQ: SVA) CoronaVac. According to the study, CoronaVac received the strongest boost from a viral vector or RNA shot, including against the Delta and Omicron coronavirus variants.

Pfizer, AstraZeneca or J&J COVID-19 Shots Boost Sinovac Regime, Brazilian Study Shows

Johnson & Johnson (JNJ) will be spinning off its Consumer Health segment over the next 18 to 24 months, which faced over $2B in talc-related litigation claims. JNJ will also be seeking bankruptcy protection for the new company, similar to other companies facing multi-billion dollar litigations.

Johnson & Johnson Stock: Spinning Off Its Litigations And Bankruptcy

Johnson & Johnson is a low beta stock, with a very long track record of strong execution.

Johnson & Johnson Is The Low Beta Stock Your Portfolio Needs

JNJ is as close to recession-proof as you can get.

Johnson & Johnson: It's Not A Matter Of If But When To Add This Stock

Brookfield Renewable Partners

Easterly Government Properties

All three have great dividends plus solid business models that are built for the long term.

3 Dividend Stocks to Buy and Hold Forever

General Motors

Starbucks

Should you be investing in these value stocks amid concerns of high inflation?

Which Stocks To Buy Now? 4 Value Stocks To Watch

American Express

General Electric

U.S. markets got off to a rocky start Friday morning. Netflix reported results Thursday afternoon that disappointed investors, primarily because of its uncertain guidance.

Earnings Previews: American Express, GE, Johnson & Johnson, 3M

J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the fourth quarter.

J&J (JNJ) to Set the Stage for Pharma Sector Q4 Earnings

Johnson & Johnson stock is scheduled to report its Q4 2021 results on Tuesday, January 25. We expect J&J to report revenues and earnings above the consensus estimates.

Will Johnson & Johnson Stock Rise After Q4 Results?

The slimmed-down healthcare company will be less diverse, but it will also have fewer problems.

Will Johnson & Johnson Be a Better Buy After Spinning Off Its Consumer Business?

Restaurant Brands

Wells Fargo

Check out these defensive stocks amid choppy markets.

Good Stocks To Invest In Right Now? 4 Defensive Stocks For Your List

Johnson & Johnson JNJ, +0.74% has long been viewed as a bellwether stock for other health care companies, given its early slot in the earnings calendar and a business model that spans everything from hip implants to rheumatoid arthritis drugs and Band-Aids.

Earnings Outlook: What's next for a J&J that will soon be split into two different companies

GlaxoSmithKline

Gilead Sciences

GlaxoSmithKline PLC ( GSK , Financial), Pfizer Inc. ( PFE , Financial) and Johnson & Johnson ( JNJ , Financial) should all know about mid-year if the shots they're developing for a common and potentially fatal virus is effective. No, the it isn't for Covid-19, but for respiratory syncytial virus, which causes an estimated 177,000 hospitalizations among older adults each year and 58,000 in children under five.

Pharma Giants Go After $10 Billion Market With RSV Drugs

Johnson & Johnson on Friday said it had agreed to pay $44 million to resolve claims that it fueled the opioid epidemic in New Mexico, a state which originally opted against participating in a nationwide settlement resolving thousands of similar cases.

J&J reaches opioid settlement with holdout state New Mexico

For Johnson & Johnson (NYSE:JNJ), Wells Fargo sees in-line Q4 FY21 despite incremental omicron headwind and underlying growth guidance for FY22 but conservative EPS.  The analyst has lowered the Q4 sales forecast by $134 million, to $24.9 billion (vs.

What To Expect When Johnson & Johnson Unveils Q4 Performance This Month

Johnson and Johnson's (NYSE: JNJ) COVID-19 vaccine booster shot is 85% effective in protecting against being hospitalized by the Omicron variant for 1-2 months after receiving it, Reuters reported citing the head of South Africa's Medical Research Council (SAMRC). Glenda Gray presented the findings of an SAMRC study at a South African health ministry briefing on the COVID-19 fourth wave.

News for Johnson & Johnson Stock (JNJ)